Ependymoma Clinical Trials

76 clinical trials for Ependymoma across international registries, including 15 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications — RECRUITING · PHASE1
• Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma — RECRUITING · NA
• Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT) — RECRUITING · PHASE1
• Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). — RECRUITING · PHASE1
• Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors — RECRUITING · PHASE2
• LET Optimized IMPT in Treating Pediatric Patients With Ependymoma — RECRUITING · PHASE1
• Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) — RECRUITING · PHASE2
• Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors — RECRUITING · PHASE1
• Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer — RECRUITING · PHASE1
• Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms — RECRUITING · PHASE1
• Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification — RECRUITING
• Systemic Biomarkers to Predict Radiation-Induced Neurocognitive Decline — RECRUITING
• Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology — RECRUITING
• Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China — RECRUITING
• PHASE 1 TRIAL OF AUTOLOGOUS HER2-SPECIFIC CAR T CELLS IN PEDIATRIC PATIENTS WITH REFRACTORY OR RECURRENT EPENDYMOMA — RECRUITING · PHASE1
• Rare CNS Tumors Outcomes &Risk — COMPLETED
• Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors — COMPLETED
• Social Determinants of Health in Glioblastoma Population — COMPLETED
• AI-Assisted MRI Molecular Subtyping in Pediatric Brain Tumors — NOT_YET_RECRUITING
• Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2) — NOT_YET_RECRUITING · PHASE2
• PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma — SUSPENDED · PHASE1
• Selumetinib for NF2-Related Schwannomatosis — NOT_YET_RECRUITING · PHASE2
• Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors — COMPLETED · PHASE2
• Methionine PET/CT Studies In Patients With Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma — ACTIVE_NOT_RECRUITING · PHASE1
• HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma — ACTIVE_NOT_RECRUITING · PHASE1
• Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG — ACTIVE_NOT_RECRUITING · NA
• Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors — NOT_YET_RECRUITING
• Pharmacoscopy for Patients With Refractory Primary Brain Tumors — NOT_YET_RECRUITING · PHASE2
• Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma — COMPLETED · PHASE3
• Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma — ACTIVE_NOT_RECRUITING · PHASE1
• A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 — ACTIVE_NOT_RECRUITING · PHASE1
• A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma — ACTIVE_NOT_RECRUITING · PHASE2
• Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod — TERMINATED · PHASE1
• B7-H3.CD28Z.CART in CNS Neoplasms — NOT_YET_RECRUITING · PHASE1
• Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG — ACTIVE_NOT_RECRUITING · PHASE2
• Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma — ACTIVE_NOT_RECRUITING · PHASE1
• EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors — COMPLETED · PHASE1
• HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Multicenter Register for Children and Young Adults With Intracranial Localized Medulloblastoma, CNS-PNET or Ependymoma — COMPLETED
• A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Molecular-Guided Therapy for Childhood Cancer — COMPLETED · NA
• Carboplatin and Bevacizumab for Recurrent Ependymoma — COMPLETED · PHASE2
• Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO) — TERMINATED
• Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma — NOT_YET_RECRUITING · PHASE1
• HUMC 1612: Optune NovoTTF-200A System — COMPLETED · PHASE1
• Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers — COMPLETED · PHASE2
• Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation — COMPLETED · PHASE2
• Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors — TERMINATED · PHASE2

Refine this search